Historically, literature reviews have come to the conclusion that there is no association between alcohol use and prostate cancer incidence. However, …
Filed under: Diagnosis, Risk | Tagged: alcohol, consumption, risk | 2 Comments »
Race, socioeconomic status, and prostate cancer
Posted on February 12, 2009 by Sitemaster
The issue of whether race and socioeconomic status impact prostate cancer treatment outcomes is fraught with all sorts of pitfalls: emotional, statistical, political, medical, societal, you name it.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ethnicity, outcome, race, risk, socioeconomic status | Leave a Comment »
The Thursday prostate cancer news: February 12, 2009
Posted on February 12, 2009 by Sitemaster
Four new reports today deal with: Higher grade disease in men diagnosed with prostate cancer because of LUTS The role of MR/MRI in prostate biopsy for carefully defined patients Risk for understaging of prostate cancer Sorenafib in treatment of patients with castration-resistant prostate cancer
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: Diagnosis, grade, LUTS, magnetic resonance, MRI, sorenafib, staging | Leave a Comment »
Can CTC counts be used as surrogate endpoints in clinical trials?
Posted on February 11, 2009 by Sitemaster
Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) counts as a prognostic factor for survival.
Filed under: Drugs in development, Management, Treatment | Tagged: circulating tumor cells, clinical trials, CTC, surrogate endpoint | Leave a Comment »
New NCCN prostate cancer management guidelines issued
Posted on February 11, 2009 by Sitemaster
The 2009 version of the National Comprehensive Cancer Network’s guidelines for treatment of prostate cancer are now available online.
Filed under: Uncategorized | Tagged: NCCN guidelines | Comments Off
Sarcosine levels: a possible new test for aggressive prostate cancer?
Posted on February 11, 2009 by Sitemaster
According to a report from the BBC today, a Letter to the Editor just published in the journal Nature links a group of small molecules produced in men with prostate cancer (and particularly a metabolite known as sarcosine) to more aggressive forms of the disease.
Filed under: Diagnosis, Management, Risk | Tagged: sarcosine | 1 Comment »
Wednesday’s prostate cancer news: February 11, 2009
Posted on February 11, 2009 by Sitemaster
Today’s news reports contain four key items: A review of the potential of phytochemicals in treatment of prostate cancer A Norwegian study on correlation between biopsy-based and post-surgical Gleason scores A retrospective study on risk for prostate cancer in men being treated with testosterone replacement therapy An announcement of new data on PSP94 in the [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, Gleason score, Miraculins, phytochemicals, PSP94, testosterone replacement, TRT | Leave a Comment »
Nerve grafting after non-nerve-sparing RP
Posted on February 10, 2009 by Sitemaster
The use of nerve grafting as a procedure to preserve erectile function in men who require neurovascular bundle resection for cancer control has long been controversial, and results over the years have been varied.
Filed under: Management, Treatment | Tagged: caverous nerve graft, neurovascular bundle | Leave a Comment »
The latest epistle from Dana Jennings …
Posted on February 10, 2009 by Sitemaster
… is entitled “Love in the Time of Prostate Cancer” and appeared in the New York Times Health blog yesterday. Enjoy!
Filed under: Living with Prostate Cancer | Leave a Comment »
Cougar Biotech and FDA agree on new abiraterone trial
Posted on February 10, 2009 by Sitemaster
According to MarketWatch, Cougar Biotechnology has announced agreement with the US Food & Drug Administration regarding the structure of another Phase III trial of abiraterone acetate in prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, clinical trial | Leave a Comment »
If you are a US citizen, it’s time to …
Posted on February 8, 2009 by Sitemaster
… call your Senators and your Congress(wo)men. Why? Go read the opinion piece by actor Patrick Swayze that appears in today’s Washington Post and that has also been posted on The “New Prostate Cancer InfoLink Social Network. That’s why. Don’t just sit on the sidelines. Take action … NOW.
Filed under: Uncategorized | Leave a Comment »
Prostate cancer awareness — the poll results
Posted on February 8, 2009 by Sitemaster
Surprisingly only 15 readers felt motivated to vote last week on the relevance of Prostate Cancer Awareness Week compared to other potential initiatives — 8/15 (53 percent) favored continuation of the current PCAW initiative compared to others, but perhaps the most telling fact is that such a small number of readers felt motivated to vote [...]
Filed under: Prevention | Tagged: awareness, poll, risk | 2 Comments »
Supplements and prostate cancer prevention: an update
Posted on February 8, 2009 by Sitemaster
An article by Collins on the CalorieLab web site offers a sound summary of “where we are” (or perhaps more accurately “where we aren’t”) with regard to the use of supplements in the prevention of prostate cancer.
Filed under: Prevention | Tagged: flaxseed, garlic, green tea, isothiocyanate, lycopene, milk, pomegranate, risk, selenium, soy, supplements, vitamin | Leave a Comment »
The weekend prostate cancer news: February 7, 2009
Posted on February 7, 2009 by Sitemaster
After yesterday’s glut of interesting new publications, we have only one significant new report today — a review article on the potential of so-called Src inhibitors in the management of metastatic, hormone-refractory disease.
Filed under: Drugs in development, Management, Treatment | Tagged: AZD0503, dasatinib, Src inhibitor | Leave a Comment »
Re-biopsy of patients with an initial diagnosis of high-grade PIN
Posted on February 6, 2009 by Sitemaster
With the increasing use of initial 12-core biopsy templates, there is a question about the interpretation of the amount of high-grade prostatic intraepithelial neoplasia (HGPIN) found on initial biopsy and risk for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: 12-core biopsy, HGPIN, high-grade prostatic intraepithelial neoplasia, risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
